Literature DB >> 15312062

The modified CAMDEX informant interview is a valid and reliable tool for use in the diagnosis of dementia in adults with Down's syndrome.

S L Ball1, A J Holland, F A Huppert, P Treppner, P Watson, J Hon.   

Abstract

BACKGROUND: Dementia because of Alzheimer's disease (AD) commonly affects older adults with Down's syndrome (DS). Methods are needed, with established concurrent and predictive validity, to facilitate the diagnostic assessment of dementia, when it is complicated by pre-existing intellectual disabilities (ID). We report on the reliability and validity of a modified version of the Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) informant interview, for use when assessing people with DS suspected as having dementia.
METHODS: As part of a previous epidemiological study of older people with DS, the CAMDEX informant interview was used to determine the prevalence of dementia. The 74 people with DS included at that time (Time 1) had also completed the Cambridge Cognitive Examination (CAMCOG), the neuropsychological assessment from the CAMDEX schedule. Fifty-six were assessed again 6 years later (Time 2). Based on the CAMDEX informant interview, nine of the 74 at Time 1, and 11 of the 56 at Time 2, were found to meet clinical criteria for AD. Forty-one scored above floor on the CAMCOG at Time 1 and were included in the analysis of cognitive decline. Concurrent validity was established by comparing diagnosis at Time 2 with independent evidence of objective decline on cognitive tasks since Time 1. Predictive validity was established by examining how accurately diagnosis at Time 1 predicted both cognitive decline and future diagnosis. Inter-rater reliability was determined by comparing the level of agreement between two raters.
RESULTS: CAMDEX-based diagnosis of AD was shown to be consistent with objectively observed cognitive decline (good concurrent validity) and to be a good predictor of future diagnosis. Although numbers are small, some support is also provided for the accuracy with which diagnosis predicts cognitive decline. Inter-rater reliability was good with Kappa > 0.8 for 91% of items and > 0.6 for all items.
CONCLUSIONS: The use of the modified CAMDEX informant interview enables the structured collection of diagnostic information, so that a valid and a reliable diagnosis of dementia can be made in those with pre-existing ID, using established diagnostic criteria.

Entities:  

Mesh:

Year:  2004        PMID: 15312062     DOI: 10.1111/j.1365-2788.2004.00630.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  35 in total

1.  Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome.

Authors:  Linda D Nelson; Prabha Siddarth; Vladimir Kepe; Kevin E Scheibel; S C Huang; Jorge R Barrio; Gary W Small
Journal:  Arch Neurol       Date:  2011-06

2.  Comparison of short and long versions of the Prudhoe Cognitive Function Test and the K-BIT in participants with intellectual impairment.

Authors:  Stephen P Tyrer; Ann Wigham; Domenic Cicchetti; Marisa Margallo-Lana; P Brian Moore; Barbara E Reid
Journal:  J Autism Dev Disord       Date:  2010-08

3.  Outcome Measures for Clinical Trials in Down Syndrome.

Authors:  Anna J Esbensen; Stephen R Hooper; Deborah Fidler; Sigan L Hartley; Jamie Edgin; Xavier Liogier d'Ardhuy; George Capone; Frances A Conners; Carolyn B Mervis; Leonard Abbeduto; Michael Rafii; Sharon J Krinsky-McHale; Tiina Urv
Journal:  Am J Intellect Dev Disabil       Date:  2017-05

4.  Identifying dementia in Down syndrome with the Severe Impairment Battery, Brief Praxis Test and Dementia Scale for People with Learning Disabilities.

Authors:  E R Wallace; J P Harp; K L Van Pelt; L M Koehl; A M Caban-Holt; A J Anderson-Mooney; G A Jicha; D D Lightner; W C Robertson; E Head; F A Schmitt
Journal:  J Intellect Disabil Res       Date:  2021-11-16

5.  Cognitive Profiles on the Severe Impairment Battery Are Similar in Alzheimer Disease and Down Syndrome With Dementia.

Authors:  Malcolm B Dick; Eric Doran; Michael Phelan; Ira T Lott
Journal:  Alzheimer Dis Assoc Disord       Date:  2016 Jul-Sep       Impact factor: 2.703

Review 6.  Rivastigmine for dementia in people with Down syndrome.

Authors:  Monica Mohan; Cathy Bennett; Peter K Carpenter
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

Review 7.  Memantine for dementia in people with Down syndrome.

Authors:  Monica Mohan; Cathy Bennett; Peter K Carpenter
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

Review 8.  Galantamine for dementia in people with Down syndrome.

Authors:  Monica Mohan; Cathy Bennett; Peter K Carpenter
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

Review 9.  Donepezil for dementia in people with Down syndrome.

Authors:  Monica Mohan; Peter K Carpenter; Cathy Bennett
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

10.  The reliability and validity of DSM 5 diagnostic criteria for neurocognitive disorder and relationship with plasma neurofilament light in a down syndrome population.

Authors:  Sarah E Pape; Tamara Al Janabi; Nicholas J Ashton; Abdul Hye; Rory Sheehan; Paul Gallagher; Bernice Knight; Anne-Marije Prins; Ken Courtenay; Vesna Jordanova; Bini Thomas; Nagarajan Perumal; Craig Forbes; Angela Hassiotis; Andre Strydom
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.